Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore.

Autor:	Wang B; Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Goh YS; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Prince T; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK., Ngoh EZX; Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Salleh SNM; Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Hor PX; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Loh CY; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Fong SW; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Hartley C; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Tan SY; Department of Infectious Diseases, Changi General Hospital, Singapore, Singapore., Young BE; National Centre for Infectious Diseases, Singapore, Singapore.; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore., Leo YS; National Centre for Infectious Diseases, Singapore, Singapore.; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore., Lye DC; National Centre for Infectious Diseases, Singapore, Singapore.; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore., Maurer-Stroh S; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Bioinformatics Institute, Agency for Science Technology and Research (A*STAR), Singapore, Singapore.; Department of Biological Sciences, National University of Singapore, Singapore, Singapore., Ng LFP; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Hiscox JA; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK., Renia L; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore. renia_laurent@IDLabs.a-star.edu.sg.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. renia_laurent@IDLabs.a-star.edu.sg.; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore. renia_laurent@IDLabs.a-star.edu.sg., Wang CI; Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore. wang_chengi@immunol.a-star.edu.sg.
Jazyk:	angličtina
Zdroj:	NPJ vaccines [NPJ Vaccines] 2021 Oct 25; Vol. 6 (1), pp. 125. Date of Electronic Publication: 2021 Oct 25.
DOI:	10.1038/s41541-021-00389-2
Abstrakt:	The rapid spreading of SARS-CoV-2 variants B.1.1.7 originated from the United Kingdom and B.1.351 from South Africa has contributed to the second wave of COVID-19 cases in the respective countries and also around the world. In this study, we employed advanced biochemical and virological methodologies to evaluate the impact of Spike mutations of these strains on the degree of protection afforded by humoral immune responses following natural infection of the ancestral SARS-CoV-2 strain during the early stages of the outbreak. We found that antibody-mediated neutralization activity was partially reduced for B.1.1.7 variant and significantly attenuated for the B.1.351 strain. We also found that mutations outside the receptor-binding domain (RBD) can strongly influence antibody binding and neutralization, cautioning the use of solely RBD mutations in evaluating vaccine efficacy. These findings highlight an urgent need to develop new SARS-CoV-2 vaccines that are not based exclusively on the ancestral SARS-CoV-2 Spike gene sequence. (© 2021. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu